MENU

Jérôme Moreaux

Ph. D Researcher at Institute of Human Genetics CNRS UPR 1142, Montpellier

Qualifications :

  • University Montpellier 1 (UM1), France, PhD, 2006, Immunology
  • University Montpellier 2 (UM2), France, Accreditation to supervise research, 2011, Health biology.

Professional experience :

  • Researcher at Institute of Human Genetics CNRS UPR 1142, Montpellier, France, 2015-present.
  • Head of Laboratory for Monitoring of Innovative Therapies. University Hospital of Montpellier, France, 2015-present.
  • Co-funder of Diag2Tec (http://www.diag2tec.com), 2015.
  • Associate Professor Haematology, University Montpellier 1, 2014.
  • Head of "Cell collection" in the Biological resource center. University Hospital of Montpellier, 2007-present.
  • Assistant of Pr Bernard KLEIN at the Laboratory of Monitoring of Novel Therapies. University Hospital of Montpellier, France, 2007-2015.
  • Researcher at INSERM-UM1 laboratory U847 and then INSERM-UM1 laboratory U1040, Montpellier, France, 2007-2015.

Honors and awards :

  • Prize K2, Cancerology (2017).
  • Member of the American Society of Hematology.

Scientific activity :

 68 publications, 3 book chapters since 2003. H index = 24.

Patents :

1- Classification, diagnosis and prognosis of multiple myeloma. Moreaux J, Pellat-Deceunynck C, Klein B. Patent n° 10305892, 2010.

2- Method for predicting multiple myeloma treatment response. Moreaux J, Klein B. Patent EP12306141.8, 2012. WO2014056928.

3- Method for predicting HDACi treatment response in Multiple Myeloma. Moreaux J, Klein B. Patent EP12306225.9, 2012. WO20144044848.

4- Method for predicting DNMTi/HDACi combination treatment response in Multiple Myeloma. Moreaux J, Klein B. EP14305404, 2014.

5- Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma. Moreaux J, Bret C, Cartron G, Constantinou A, Pasero P. EP14306201. 2014.

6- Methods and pharmaceutical compositions for the treatment of multiple myeloma. Moreaux J, Herviou L, Izard F, Grimaud C, Julien E. EP16305176. 2016.

7- Methods using a marker of multiple myeloma. Moreaux J, Viziteu E, Constantinou A, Pasero P. EP16305682. 2016.

8- Method for the prognosis of multiple myeloma. Aleterre E, Moreaux J. EP16305651. 2016.

9- Moreaux J, Klein B, Requirand G, Raimbault, S, Alaterre E, Garcia J. Detection of minimal residual disease in multiple myeloma. FR1654514. 2016.

10- Method for the in vitro prognosis of individuals having Multiple Myeloma and method for the treatment thereof. Cavalli G, Kassambara A, Herviou L. Moreaux J. EP16306436.3. 2016.

Main Grants since 2012 :

  • 2012-2014: Languedoc Roussillon region – Europe FEDER. PI: J Moreaux.
  • 2012-2013: Cancéropôle Grand Sud-Ouest. PI: J Moreaux.
  • 2013-2015: ARC subvention. PI: J Moreaux.
  • 2013-2015: ANR Emergence (Epigenetic Targeted Treatment of Multiple Myeloma). Coordinator: B KLEIN.
  • 2014-2016: Languedoc Roussillon region - “Chercheur d’avenir”. PI: J Moreaux.
  • 2014-2016 : Fondation de France. PI : J Moreaux.
  • 2014-2016 : French Foundation for the Research on Myeloma and Gammopathies.
  • PI : J Moreaux.
  • 2015-2016 : Maturation funding SATT AxLR. PI : J Moreaux.
  • 2015-2017 : Cancer Plan: Epigenetics and cancer - Multiple Myeloma: Epigenetic Mining and Therapeutic Targeting. Coordinator : J Moreaux.
  • 2015-2018 : French National Cancer Institute, PLBIO 2015. Role of RECQ helicases in Mulitple Myeloma. Coordinator : J Moreaux.
  • 2017-2020 : R&D collaborative project-FEDER/Region. Synthetic lethality in hematological malignancies. IGH – P Pasero, CHU Montpellier – J Moreaux, BCI Pharma and Diag2Tec.
  • 2017-2020 : AF3M grant. Targeting DNA repair pathways to overcome drug resistance in Multiple Myeloma.  PI: J Moreaux.

Last scientific publications :

1- Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell. Kassambara A, Jourdan M, Bruyer A, Robert N, Pantesco V, Elemento O, Klein B, Moreaux J. Nucleic Acids Res. 2017 Apr 29.


2- RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Viziteu E, Klein B, Basbous J, Lin YL, Hirtz C, Gourzones C, Tiers L, Bruyer A, Vincent L, Gandmougin C, Seckinger A, Goldschmidt H, Constantinou A, Pasero P, Hose D, Moreaux J. Leukemia. 2017. Mar 10.

3- Hypoxia favors the generation of human plasma cells. Schoenhals M, Jourdan M, Bruyer A, Kassambara A, Klein B, Moreaux J. Cell Cycle. 2017 May 2:1-14

4- Chetomin, targeting HIF-1/p300 complex, exhibits antitumor activity in multiple myeloma. Viziteu E, Grandmougin C, Goldschmidt H, Seckinger A, Hose D, Klein B, Moreaux J. British Journal of Cancer. 2016 Mar 1;114(5):519-23.

5- EZH2 in normal hematopoiesis and hematological malignancies. Herviou L, Cavalli G, Cartron G, Klein B, Moreaux J. Oncotarget. 2016 Jan 19;7(3):2284-96.